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Introduction {#sec1}
============

Most natural proteins are only marginally stable ([@bib27]). Thus, taken out of their natural context, through either overexpression, heterologous expression, or changes in environmental conditions, many proteins misfold and aggregate. The most general origin of overexpression challenges is low stability of the protein's native, functional state relative to alternative nonfunctional or aggregation-prone states. By designing variants with more favorable native-state energy, yields of soluble and functional protein obtained by heterologous overexpression can be dramatically increased, alongside other merits such as longer storage and usage lifetimes and enhanced engineering potential.

Engineering stable protein variants is a widely pursued goal. Methods based on phylogenetic analysis ([@bib25], [@bib32]) and structure-based rational or computational design ([@bib6], [@bib16], [@bib21], [@bib23]) yielded proteins with improved stability and higher functional expression ([@bib27]). Individual mutations, however, contribute little to stability (typically ≤1 kcal/mol) ([@bib40]), whereas stabilizing large and poorly expressed proteins typically requires many mutations. However, since even a single severely destabilizing mutation can undermine the benefit accruing from all others, high prediction accuracy is essential. Despite improvements in accuracy, existing approaches have a relatively high probability of inadvertently introducing disruptive mutations (false-positive predictions) ([@bib6], [@bib27], [@bib30]). Published efforts to stabilize large proteins therefore either incorporate only a few predicted stabilizing mutations (typically ≤4) at each experimental step or use library approaches to identify optimal combinations of stabilizing mutations ([@bib19], [@bib33], [@bib36], [@bib37], [@bib38]). Such approaches are laborious and impractical for proteins without established medium-to-high throughput screens, let alone for proteins of unknown function. To address the demand for stabilizing large, recalcitrant proteins by a wide range of researchers, who lack background in computational design, we developed an automated algorithm based on atomistic Rosetta modeling and phylogenetic sequence information. We specifically aimed to develop a general method that minimizes false-positive predictions to ensure that only a few variants need to be experimentally tested to achieve high functional yields (ideally, just one variant). We applied this algorithm to four different enzymes and one protein of unknown function. In each case, up to five variants were designed as the default output, encoding from 9 to 67 mutations relative to wild-type. These variants exhibited enhanced bacterial expression yields and stability, without sacrificing or altering activity.

Design {#sec2}
======

Computational Mutation Scanning Minimizes False-Positive Mutations {#sec2.1}
------------------------------------------------------------------

To address the challenge of designing variants with a large net stabilizing effect, yet without modifying their function, our computational process began by scanning the natural sequence diversity. For every target wild-type sequence, we generated a sequence alignment, from which we computed a position-specific substitution matrix (PSSM) ([@bib2]); the PSSM represents the log-likelihood of observing any of the 20 amino acids at each position. At every amino acid position, "allowed" mutations were defined as those with a favorable PSSM score (≥0). The rationale for restricting the allowed sequence space through the alignment scan is that, in general, deleterious mutations are purged by natural selection; purging is not absolute, however, and less favorable amino acids may occur at certain positions. Indeed, mutation to the most frequently observed amino acid often increases stability (the consensus effect) ([@bib25], [@bib27], [@bib32]). However, our approach does not implement the consensus per se. Foremost, the alignment scan eliminates mutations that are rare or never seen in the natural diversity, rather than strictly selecting the most frequent amino acid. Next, we applied Rosetta computational mutation scanning ([@bib37]), wherein each "allowed" mutation from the previous step was singly modeled against the background of the wild-type structure, and the energy difference between the wild-type and the single-point mutant was calculated (ΔΔ*G*~*cal*c~). By computing the effects of each mutation singly, rather than in combination with others, we restricted design choices to mutations that were likely to make additive contributions to stability, rather than nonadditive and context-dependent contributions, thereby minimizing the risk of false positives. We thereby defined the space of "potentially stabilizing" mutations as mutations with ΔΔ*G*~*cal*c~ ≤−0.45 Rosetta energy units (R.e.u.); we chose this cutoff rather than 0 R.e.u. to further lower the risk of false positives, as indicated by the systematic evaluation described below. As a final step, we used Rosetta combinatorial sequence design to find an optimal combination of mutations within the space of potentially stabilizing mutations. Additionally, we used lower ΔΔ*G*~*cal*c~ cutoffs to select potentially stabilizing mutations prior to combinatorial sequence design, thereby generating several designs for experimental testing (see [Data S1](#mmc2){ref-type="supplementary-material"} available online).

The choice of mutations at Gly416 in human acetylcholinesterase (hAChE) illustrates the role of these two filters (alignment scan and computational mutation scanning) in pruning false positives ([Figure 1](#fig1){ref-type="fig"}A). Position 416 is located on a partially exposed helical surface, where the small and flexible amino acid Gly is likely to destabilize hAChE. Indeed, in the alignment of AChE homologs, Gly is infrequent, and His is the most prevalent amino acid. Modeling shows, however, that in the specific context of hAChE, His adopts a strained side-chain conformation; in contrast, Gln, the third most prevalent amino acid, is predicted to be most stabilizing owing to its high helical propensity and favorable hydrogen bonding with Tyr503. The combined filter therefore favors Gln over His for downstream design calculations.

To systematically evaluate the ability of our filtering method to identify stabilizing mutations, we compared its output to published experimental data on the stability effects of single-point mutations in the enzymes fungal endoglucanase Cel5A and yeast triosephosphate isomerase (TIM) ([Figure 1](#fig1){ref-type="fig"}B; [Table 1](#tbl1){ref-type="table"}) ([@bib33], [@bib36]). The two filters (PSSM and Rosetta mutational scanning using ΔΔ*G*~*cal*c~ ≤−0.45 R.e.u. as cutoff) eliminated all the severely destabilizing mutations (and 99.6% of all destabilizing mutations) and retained one-third and two-thirds of the experimentally verified stabilizing mutations in Cel5A and TIM, respectively. Thus, for both enzymes, our method identified a large fraction of the known stabilizing mutations, while excluding false positives almost entirely. The energy cutoff emphasizes the importance of minimizing false-positive predictions, that is, mutations that are experimentally destabilizing but are computationally assessed as favorable; for instance, in the case of Cel5A, using ΔΔ*G*~*cal*c~ ≤0 R.e.u. as cutoff would correctly predict four additional stabilizing mutations but would introduce eight more destabilizing mutations. False-negative predictions---that is, mutations that are stabilizing in experiment but are considered destabilizing by modeling---could not be attributed to a single modeling error ([Table S1](#mmc1){ref-type="supplementary-material"}). Specifically, out of 22 false negatives in Cel5A, eight were filtered because they are unlikely according to the sequence alignment (PSSM score \<0), and four showed ΔΔ*G*~*cal*c~ in the range −0.45--0 R.e.u., thereby missing the energy threshold by a small margin. Of the ten remaining false negatives, three occurred at core positions, where energy calculations typically penalize mutations, and two were mutations to proline. Improvements in the energy function and the conformation-relaxation procedure may in the future increase accuracy, and the analysis reported here provides a benchmark for such improvements.

Results {#sec3}
=======

Designed hAChE with Nearly 2,000-Fold Higher Bacterial Expression and Intact Activity {#sec3.1}
-------------------------------------------------------------------------------------

We applied our design strategy to human acetylcholinesterase (hAChE), a 60 kDa enzyme responsible for terminating synaptic transmission at cholinergic synapses by rapidly hydrolyzing the neurotransmitter acetylcholine (ACh) ([@bib34]). Although AChE is potentially useful for detection and detoxification of organophosphate nerve agents and pesticides, hAChE is currently produced by costly procedures involving purification from blood erythrocyte membranes, or using plant or mammalian expression systems. Previous attempts to express hAChE in bacteria resulted in extremely low levels of soluble and active protein ([@bib13]). AChE's active site is located at the bottom of a deep gorge that penetrates half way (20 Å) into the enzyme, and mutations along the gorge can reduce ACh hydrolysis rates by up to 1,000-fold ([@bib29]). To increase the stability and expression levels of hAChE without altering its activity, we imposed a further restriction on the allowed sequence space of the newly designed hAChE: in all Rosetta modeling simulations, the side-chain conformations of amino acids within 8 Å of the reversible inhibitor E2020, which spans the full length of the active-site gorge ([@bib9]), had to remain as in the native hAChE structure ([Table S2](#mmc1){ref-type="supplementary-material"}). The latter restriction, in combination with the two above-described filters, dramatically reduced the sequence space available for design. The theoretical sequence space for hAChE, a 550-residue enzyme, is 10^750^, a formidable number inaccessible even for advanced modeling algorithms. The size of the reduced sequence space, by contrast, was 10^31^ sequences, equivalent to complete computational design of a 24-amino acid peptide, a challenge solved already in the 1990s ([@bib10]). We noted that the reduced sequence space led to convergence of combinatorial sequence optimization to identical, or nearly identical, sequences for any given ΔΔ*G*~*cal*c~ cutoff; this convergence, which is not usual in computational design ([@bib14]), is a prerequisite for reproducibility and usage by nonexperts.

Given AChE's large size, we designed five alternatives using different ΔΔ*G*~*cal*c~ thresholds, with 17--67 mutations relative to hAChE ([Table S3](#mmc1){ref-type="supplementary-material"}; [Data S2](#mmc3){ref-type="supplementary-material"}), and subjected them to experimental testing. Synthetic genes encoding wild-type hAChE and the five designs were optimized for bacterial translation efficiency, fused to the C terminus of thioredoxin, and expressed in *E. coli* ShuffleT7express cells to facilitate disulfide-bond formation. In SDS-PAGE gels of supernatant fractions from bacterial lysates, the AChE band overlapped with other bands, precluding visual quantification. Nevertheless, because the designed variants' specific activity was found to be nearly identical to the wild-type's ([Table 2](#tbl2){ref-type="table"}), we could quantify the relative levels of soluble and active enzyme by measuring AChE activity in crude lysates. The five designs showed ≥100-fold higher lysate ACh-hydrolysis rates compared to hAChE, with the best design, dAChE4 ([Figure 2](#fig2){ref-type="fig"}A; 51 mutations), exhibiting an almost 2,000-fold higher rate ([Figure 2](#fig2){ref-type="fig"}B). Furthermore, due to its extremely low soluble expression, hAChE could not be purified from crude cell lysates, whereas the designed variants were readily purified to homogeneity, with dAChE4 yields in standard shaker flasks approaching 2 mg protein per liter of bacterial culture ([Table S4](#mmc1){ref-type="supplementary-material"}).

The designed AChE mutations are scattered throughout the enzyme and show typical characteristics of stabilizing mutations, including improved core packing, higher backbone rigidity, and increased surface polarity ([Figure 2](#fig2){ref-type="fig"}A). In agreement with the design strategy and the higher levels of soluble and functional enzyme, we observed increased resistance to heat inactivation of up to 20°C relative to the *E. coli*-expressed hAChE ([Figure 2](#fig2){ref-type="fig"}C) and to hAChE expressed in mammalian cells ([Table 2](#tbl2){ref-type="table"}). The designs hydrolyzed ACh at rates that are within a 2-fold margin of hAChE rates, and displayed inactivation-rate constants by the nerve agent VX that are nearly identical to hAChE (the largest deviation was observed for dAChE3, which exhibited a 2.5-fold lower inactivation rate; [Table 2](#tbl2){ref-type="table"}).

The above observations of nearly identical activity profiles of the designed and wild-type AChEs suggested that the designed enzymes' active sites are essentially identical to that of hAChE. To verify this, we conducted crystallization trials on dAChE4, the design exhibiting the highest bacterial-expression yields. We noted that, in contrast to various natural AChEs studied by us, large crystals formed already within a few days and more reproducibly. dAChE4's structure was solved at 2.6Å resolution, thus yielding, to the best of our knowledge, the first structure of an AChE expressed in a prokaryote ([Table S5](#mmc1){ref-type="supplementary-material"}). dAChE4's structure is very similar to that of wild-type hAChE, with a 0.7 Å root-mean-square deviation (rmsd) over Cα atoms. Residues at the catalytic gorge aligned particularly well, with an all-atom rmsd of only 0.125Å ([Figure 2](#fig2){ref-type="fig"}D). Thus, despite 51 mutations relative to wild-type, ∼2,000-fold gain in bacterial expression levels, and 20°C higher heat tolerance, dAChE4 is virtually indistinguishable in its active site from hAChE (differences in other parts of the enzyme are shown in [Figure S1](#mmc1){ref-type="supplementary-material"} and online at <http://proteopedia.org/w/Journal:Molecular_Cell:1>). dAChE4 can therefore serve in future structural studies of inhibitors that target the AChE active site.

Other Designed Enzymes Show High Stability and/or Soluble Expression {#sec3.2}
--------------------------------------------------------------------

We applied our algorithm to two other human enzymes---the histone deacylase SIRT6, the human DNA methyltransferase Dnmt3a, and a bacterial phosphotriesterase dubbed PTE. Being the only enzyme known to have actually evolved to degrade organophosphates (OPs), PTE is of considerable biotechnological potential for decontamination and detoxification of OPs, including nerve agents. However, PTE detoxifies most nerve agents at rates too slow for practical applications. Wild-type PTE was previously engineered for higher expression ([@bib31]) and hydrolysis rates toward various OPs ([@bib4], [@bib8]). Introduction of function-altering mutations, however, destabilized the enzyme, as is often the case for laboratory-evolved enzymes ([@bib35]); thus, stabilization is a prerequisite for further engineering ([@bib5]). We designed three alternatives using different ΔΔ*G*~*cal*c~ thresholds, encoding 9--28 mutations relative to wild-type PTE ([Table S3](#mmc1){ref-type="supplementary-material"}), and subjected them to experimental testing. Synthetic genes encoding the three designs and PTE-S5, a published variant encoding three mutations, which displays ∼20-fold higher expression levels compared to wild-type ([@bib31]), were optimized for bacterial translation efficiency, fused to maltose-binding protein, and expressed in *E. coli* GG48 cells. All three designs displayed increased levels of soluble, functional enzyme compared to PTE-S5, which already displays higher expression levels than wild-type ([Table 3](#tbl3){ref-type="table"}). Two of the three designs showed ∼10°C higher tolerance to heat inactivation relative to PTE-S5, with no significant change in activity toward the OP substrate paraoxon ([Table 3](#tbl3){ref-type="table"}; [Figure S2](#mmc1){ref-type="supplementary-material"}A). Another noteworthy outcome of stabilization design was increased metal affinity. PTE is a metalloenzyme bearing two active-site metals, typically Zn^+2^ ([@bib3]). Directed evolution of wild-type PTE for higher expression (PTE-S5) led to a significant decrease in metal affinity---a major practical drawback for applications in conditions in which Zn^+2^ cannot be supplemented. The designed variant dPTE2, which contained 19 mutations and exhibited the highest tolerance to heat inactivation, also exhibited a marked increase in metal affinity compared to PTE-S5, approaching the affinity of wild-type PTE ([Figures 3](#fig3){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}B; [Table 3](#tbl3){ref-type="table"}).

SIRT6 is an ADP-ribosylase and NAD^+^-dependent deacylase that removes acyl groups from acylated lysines, thereby regulating several essential cellular processes ([@bib22]). The low bacterial-expression levels of human SIRT6 (hSIRT6), and its weak deacylation activity relative to SIRT1, limit its study. The designed variant (dSIRT6) contained 11 mutations relative to hSIRT6 ([Tables S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}). It was expressed in *E. coli* and purified to homogeneity with yields of 20 mg per liter culture, an ∼5-fold increase relative to hSIRT6, and its deacylase activity was 60% higher than hSIRT6's ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). We subsequently incorporated the design mutations on the background of an engineered hSIRT6 variant dubbed E1, which contains three mutations relative to hSIRT6 (our unpublished data). E1 exhibits increased deacylation activity compared to hSIRT6 but 3-fold lower expression levels in human cell lines. In contrast, the designed variant dE1 recapitulates hSIRT6's expression levels in human cell lines while maintaining high deacylation activity ([Figure 3](#fig3){ref-type="fig"}B). Given the beneficial effects of SIRT6 overexpression on longevity in mice ([@bib18]), our designed mutant can be used to establish a correlation between SIRT6's deacylation rates and its physiological function.

In the case of human Dnmt3a (hDnmt3a), soluble and active fractions of the human enzyme can be obtained by *E. coli* expression, but enzyme activity is very low. We tested one design dDnmt3a containing 14 mutations relative to hDnmt3a ([Tables S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}). In contrast to all other designs, the designed dDnmt3a showed significantly lower expression levels than hDnmt3a in *E. coli* ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D). Nonetheless, it exhibited nearly 10-fold higher specific activity ([Figure 3](#fig3){ref-type="fig"}C), suggesting that hDnmt3a preparations contain a significant fraction of soluble but inactive or poorly active enzyme. Therefore, although Dnmt3a failed to meet our design method's success criteria (higher stability and soluble expression), it significantly increased the protein's functional yield.

A Webserver for Protein Stabilization {#sec3.3}
-------------------------------------

Encouraged by the consistently positive results presented above, we implemented the algorithm as a webserver, called the *P*rotein *R*epair *O*ne *S*top *S*hop (PROSS, <http://pross.weizmann.ac.il>). Following their request for assistance in solving a critical expression and stability question regarding the human myocilin OLF domain (hMyoc-OLF), two of the authors (S.E.H. and R.L.L.) were granted unsupervised access to the webserver. OLF domains are found in extracellular proteins of multicellular organisms. A number of OLF domains have been implicated in human disease, but the function(s) of most OLF domains remains elusive. The best-studied OLF domain is that of hMyoc-OLF, in which more than 100 nonsynonymous mutations are implicated in inherited forms of open-angle glaucoma. Mutations documented in patients lead to destabilized myocilin protein that forms cytotoxic aggregates ([@bib7], [@bib39]). S.E.H. and R.L.L. therefore posited that mutations that confer enhanced stability might reduce hMyoc-OLF's propensity to misfold at physiological temperatures.

Three hMyoc-OLF structures (PDB: [4WXQ](pdb:4WXQ){#intref0025}, [4WXS](pdb:4WXS){#intref0030}, and 4WXU) were submitted to PROSS, producing seven designs for each structure with 5--25 mutations each. From all suggested point mutations, S.E.H. and R.L.L. manually derived one variant (dMyoc-OLF) comprising 21 mutations. Although hMyoc-OLF binds Ca^+2^ ([@bib11]), the physiological role of Ca^+2^ binding is still unknown; nevertheless, the Ca^+2^-binding positions remained unchanged, reflecting the high sequence and structural constraints acting on them. Furthermore, none of the design mutations have been implicated in human disease, supporting the notion that the disease-associated mutations are destabilizing.

dMyoc-OLF and hMyoc-OLF were expressed in *E. coli* fused to maltose-binding protein (MBP-OLF). The designed variant gave an order of magnitude higher yield than hMyoc-OLF ([Table S6](#mmc1){ref-type="supplementary-material"}). In addition, whereas the purified hMyoc-OLF comprises a mixture of a soluble MBP-OLF-aggregate and the properly folded monomer ([@bib7]), the designed variant was almost exclusively monomeric, and also exhibited a 16.8°C higher melting temperature (*T*~*m*~) than hMyoc-OLF ([Figures 3](#fig3){ref-type="fig"}D and 3E). This is the highest *T*~*m*~ measured so far for Myoc-OLF, nearly the same as that of the gliomedin OLF domain that lacks a Ca^+2^-binding site ([@bib15]). Nonetheless, as indicated by the *T*~*m*~ increase in the presence of Ca^+2^ ([Figure 3](#fig3){ref-type="fig"}D; [Table S6](#mmc1){ref-type="supplementary-material"}), Ca^+2^ binding was retained in dMyoc-OLF. The designed variant dMyoc-OLF is therefore a starting point for detailed OLF structure-function analysis.

Discussion {#sec4}
==========

Most existing stability-design methods focus on one element or another of protein stability. For instance, some methods introduce disulfides or prolines, while others optimize core packing ([@bib6], [@bib21]) and increase surface polarity ([@bib27]) and charge ([@bib23]). Our design algorithm, by contrast, selects for all amino acid mutations that optimize the protein's computed energy, subject to constraints inferred from homologous sequences. It thereby generates designs that improve a range of molecular parameters that are associated with stability ([Table 4](#tbl4){ref-type="table"}) while preserving function. We find, furthermore, that in the various proteins studied here, the algorithm implemented solutions that appear to selectively tackle specific defects of each protein. For instance, 17 of the 51 mutations in design dAChE4 impact core positions, a very large number compared to previous design studies that targeted protein cores ([@bib6], [@bib21]). Indeed, natural AChE structures contain unusually large core cavities ([@bib20]). In design dPTE2, by contrast, only two core mutations were implemented, and the net negative charge increased by 13 units, shifting the isoelectic point (pI) from a near-neutral value of 6.7 for the wild-type to 5.0; indeed, near-neutral pI is often associated with poor solubility, and surface "supercharging" has been used by others to improve thermal stability ([@bib23]). The stability considerations, however, do not come at the expense of functional constraints. In Dnmt3a, for example, the positive net charge and basic pI are fully conserved as expected for a DNA-binding protein. We conclude that the combination of evolutionary constraints, selection of mutations that individually contribute to computed stability, and combinatorial sequence optimization within the space of these mutations can address a broad range of stability defects in various proteins without affecting their original molecular functions.

The case studies discussed here represent a diverse group of proteins belonging to different fold families (TIM barrel, β-propeller, and α/β hydrolase fold) and displaying different activities. In each case, the wild-type protein and variants previously engineered using traditional methods suffer from low stability, as manifested by intolerance to high temperature and function-modifying mutations or by low solubility, heterologous expression, cofactor affinity, or specific activity. That a single fully automated method that only considers phylogenetic constraints and optimizes the native state's energy is able to address these diverse challenges without sacrificing function demonstrates that the underlying source of these problems is the native state's marginal stability. Furthermore, the stability-design method has the potential to optimize proteins used as scaffolds for de novo binder or enzyme design, where low stability and expression levels have been limiting ([@bib14], [@bib19]).

Limitations {#sec4.1}
-----------

The stability design algorithm requires a few dozen unique sequence homologs and an atomic structure of the target protein. With the burgeoning of sequence databases, the first requirement is likely to be met with few exceptions; the second, however, may be an impediment, particularly since low protein yields and stability negatively impact structure determination. To expand beyond experimentally determined structures, homology models may be used, and it remains to be seen whether they provide sufficient accuracy for atomistic stability-design calculations.

Experimental Procedures {#sec5}
=======================

Computational Procedures {#sec5.1}
------------------------

### Phylogenetic Sequence Constraints {#sec5.1.1}

For every query sequence, homologous sequences were collected using the BLASTP algorithm ([@bib1]) on the nonredundant (nr) database, with the maximum number of hits set to 500 and the *e* value to 10^−4^. All other parameters were set to default values. Hits were excluded if they covered less than 60% of the query sequence or if their sequence identity to the query sequence was lower than 30% (28% for PTE due to the low diversity of homologs at \>30% sequence identity). The remaining sequences were clustered using cd-hit ([@bib26]), with a clustering threshold of 90% and default parameters.

MUSCLE ([@bib12]) was used with default parameters to derive a multiple sequence alignment (MSA) from the clustered sequences. Gaps in the alignment between the query and any homolog often occur within loop regions and may reflect differences in the local backbone conformation. To reduce alignment uncertainty, we detected secondary-structure elements in the query protein structure (using DSSP \[[@bib17]\]) and eliminated subsequences in homologs that contained gaps in loop segments that intervene between any two secondary-structure elements relative to the query. In effect, for every loop region this procedure generated a specific alignment that only comprised homologous sequences with no insertions or deletions relative to the query. Since this feature of the stability-design algorithm had not yet been implemented when we designed AChE and Dnmt3a, these two proteins were designed with default MUSCLE alignments, containing information from all homologs in loop regions.

Given the alignments of each query sequence, we computed a position-specific scoring matrix (PSSM) using the PSI-BLAST algorithm ([@bib2]). The PSSM represents the log probability of observing each of the 20 amino acids at each position in the query. Non-negative PSSM scores are considered likely to occur in evolution and define the space of allowed mutations.

### Structure-Based Constraints {#sec5.1.2}

To prevent activity loss, residues within 8 Å of small-molecule ligands observed in the active site (hAChE and Dnmt3a), or within 5 Å of metal cofactors (PTE), DNA chains (Dnmt3a) and protein ligands (SIRT6) were held fixed throughout all Rosetta simulations. In homo-oligomer structures (PTE and AChE), residues within 5Å of the oligomer interface were held fixed. For PTE and SIRT6, some of the active-site constraints were defined using an alignment to another, ligand-bound structure, namely residues within 8Å of DPJ in 4NP7 for PTE, and residues within 5Å of chain F in 3ZG6 for SIRT6 ([Table S2](#mmc1){ref-type="supplementary-material"}). Two positions on either side of missing density and residues at the termini (if the termini made no interactions with other parts of the protein) were not allowed to mutate. For hSIRT6, four residues that were found to increase activity in previous laboratory-evolution experiments were modeled prior to simulation, and not allowed to mutate (see [Table S2](#mmc1){ref-type="supplementary-material"}). In the PROSS webserver, active-site constraints follow the same thresholds defined above, and the user may specify any other residue to be held fixed during the simulations through an interactive HTML form.

### Rosetta Structure Modeling and Design {#sec5.1.3}

See [Data S1](#mmc2){ref-type="supplementary-material"} online for RosettaScripts, flags, and command lines.

Two energy functions were alternated throughout the simulations: the all-atom "hard-repulsive" Rosetta energy function (talaris2014) ([@bib28]), which is dominated by van der Waals, hydrogen bonding, implicit solvation, and Coulomb electrostatics with a distance-dependent dielectric coefficient, and a "soft-repulsive" version of this energy function (soft-rep), where van der Waals overlaps and residue conformational strain are downweighted. The two energy functions were augmented with harmonic backbone coordinate restraints set to the coordinates observed in the PDB structure, and with a term that favors mutations with a higher PSSM score.

We refined each PDB structure by four iterations of side-chain packing (except in active-site residues) and side-chain and backbone minimization, saving the minimum-energy structure. For hAChE, the largest protein tested here, refinement calculations took, on average, 2.5 hr per trajectory ([Data S1](#mmc2){ref-type="supplementary-material"}).

Computational mutation scanning was applied to the refined structure using the FilterScan mover in Rosetta ([@bib37]). At every position, each allowed mutation (that is, every amino acid identity with PSSM score ≥0) was modeled singly against the background of the refined structure. Protein sidechains within 8 Å of the modeled mutation were repacked, and side-chain and constrained backbone minimization were used to accommodate the mutation. The energy difference between the refined structure and the optimized configuration of the single-point mutant was calculated using talaris2014 ([@bib28]). Seven energy thresholds were used to define different mutation spaces (−0.45, −0.75, −1.0, −1.25, −1.5, −1.8, and −2.0 R.e.u.). Mutation scanning is the most time-consuming step in the calculation, taking between 30 s and 6 min per position (1 min per position on average for hAChE) using a standard CPU ([Data S1](#mmc2){ref-type="supplementary-material"}). The procedure can be parallelized using a computer cluster, as implemented in the PROSS webserver.

For Dnmt3a, nine mutations were eliminated from the allowed sequence space since they showed exceptionally high and unexpected changes in their Rosetta backbone-omega energy, probably due to the poor crystallographic resolution of the input PDB structure ([Table S2](#mmc1){ref-type="supplementary-material"}).

For each of the sequence spaces of potentially stabilizing mutations, combinatorial sequence optimization was implemented. Starting from the refined structure, we imposed coordinate restraints relative to the coordinates in the PDB file, and implemented four iterations of sequence design, side-chain, and backbone minimization, while alternating soft and hard repulsive potentials. For AChE, each design trajectory took ∼2.5 hr on average ([Data S1](#mmc1){ref-type="supplementary-material"}).

Design Model Analysis {#sec5.2}
---------------------

Sequence and structural features of designed variants were compared to the sequence and structure of the wild-type protein. The differences in the number of salt bridges and hydrogen bonds were evaluated using the Rosetta FeaturesReporter suite ([@bib24], [@bib28]), with a salt-bridge interaction defined as two counter charges within less than 5.5Å. Buried residues were defined as residues with \>22 and \>75 neighboring nonhydrogen atoms within 10 Å and 12 Å, respectively. Protein isoelectric points (pI) were calculated using the ExPASy webserver (<http://web.expasy.org/compute_pi>).

For experimental procedures, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} online.

For DNA and protein sequences, see [Data S2](#mmc3){ref-type="supplementary-material"}.
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![Eliminating Potentially Destabilizing Mutations through Homologous-Sequence Analysis and Computational Mutation Scanning\
(A) (Left) Sequence logo for hAChE position Gly416. Letter height represents the respective amino acid's frequency in an alignment of homologous AChE sequences. The evolutionarily "allowed" sequence space (PSSM scores ≥0) at position 416 includes the nine amino acids shown. (Right) Structural models of mutations to the evolutionarily favored amino acid His, and to Gln, which is favored by Rosetta energy calculations. The His side chain is strained due to its proximity to the bulky Tyr503 aromatic ring, whereas the Gln side chain is relaxed and forms a favorable hydrogen bond with Tyr503 (dashed line).\
(B) Computational mutation scanning correctly identifies all of the destabilizing mutations and ⅔ of the stabilizing mutations in yeast triosephosphate isomerase (TIM). [@bib33] used consensus design to predict 23 mutations that would stabilize yeast TIM and measured each mutant's *T*~*m*~ difference relative to wild-type (Δ*T*~*m*~). We used computational mutation scanning to predict the effects of each mutation on stability (ΔΔ*G*~*calc*~). Four mutations were experimentally found to be highly deleterious, resulting in no functional expression, and therefore the *T*~*m*~ for these could not be measured (open circles); these four mutations have highly unfavorable ΔΔ*G*~c*alc*~ values (\>4.6 Rosetta energy units; R.e.u.).\
See also [Table S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Design of a Stable hAChE variant and Its Functional Expression in Bacteria\
(A) The structural underpinnings of stabilization in the designed variant dAChE4. Wild-type hAChE is shown in blue and 51 mutated positions, which are distributed throughout dAChE4, are indicated by orange spheres. Thumbnails highlight stabilizing effects of selected mutations.\
(B) Bacterial lysate activity levels of designed AChEs normalized to hAChE activity. Crude lysates were derived from 250 ml flasks (medium scale) or 0.5 ml *E. coli* cultures grown in a 96-well plate (small scale). The higher activity levels in the designed variants reflect higher levels of soluble, functional enzyme.\
(C) Designed AChE variants (colored lines) show higher resistance to heat inactivation compared to hAChE (black). Residual activities following incubation at different temperatures were measured in bacterial lysates and normalized to the activity in nontreated lysates.\
(D) Sub-Ångstrom accuracy in alignment of key residues in the vicinity of the catalytic triad in the crystallographic structure of dAChE4 (PDB: [5HQ3](pdb:5HQ3){#intref0045}, yellow) compared to hAChE (PDB: [4EY4](pdb:4EY4){#intref0050}, green).\
See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Tables S2--S5](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Higher Expression, Stability, and Activity of Designed Variants of PTE, SIRT6, Dnmt3a, and Myoc-OLF\
(A) Compared to the previously engineered variant PTE-S5 ([@bib31]), the design dPTE2 shows higher resistance to inactivation by the metal chelator 1,10-phenanthroline (50 μM), indicating higher metal affinity and stability.\
(B) (Upper panel) The previously engineered E1 variant of hSIRT6 shows a 3-fold decline in in vivo expression levels, whereas following computational design, dSIRT6-E1 (denoted as dE1) recapitulates hSIRT6's expression levels (western blot quantified using ImageJ). Actin expression levels are provided as control. (Lower panel) dE1 exhibits higher in vivo histone H3 Lys56-deacylation activity compared to hSIRT6. HY denotes a loss-of-function mutant of hSIRT6; H3 expression levels are provided as control.\
(C) The designed variant dDnmt3A shows 10-fold higher DNA-methylation compared to hDnmt3a as determined by the levels of incorporation of H^3^-methyl groups in the presence of equal enzyme concentrations.\
(D) dMyoc-OLF is more thermostable than hMyoc-OLF, and addition of Ca^+2^ further stabilizes it.\
(E) Size-exclusion chromatography of MBP-fused hMyoc-OLF and dMyoc-OLF indicated a significant aggregated fraction in hMyoc-OLF, as previously described ([@bib7]), and a minor aggregated fraction in dMyoc-OLF. (Inset) SDS-PAGE analysis of dMyoc-OLF. Lane 1, molecular weight standards (kDa); lanes 2--6, size exclusion fractions as labeled in chromatogram.\
See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"} and [Tables S2](#mmc1){ref-type="supplementary-material"}, [S3](#mmc1){ref-type="supplementary-material"}, and [S6](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

###### 

Computational Mutation Scanning versus Experimental Point Mutations in Fungal Endoglucanase 5A

  Mutations                                            Stabilizing[a](#tblfn1){ref-type="table-fn"}   Destabilizing[a](#tblfn1){ref-type="table-fn"}   Total
  ---------------------------------------------------- ---------------------------------------------- ------------------------------------------------ -------
  True predictions[b](#tblfn2){ref-type="table-fn"}    12 (35%)                                       230 (99.6%)                                      242
  False predictions[b](#tblfn2){ref-type="table-fn"}   22 (65%)                                       1 (0.4%)                                         23
  Total                                                34                                             231                                              265

Mutations were experimentally assayed by heat inactivation ([@bib36]; raw data kindly provided by D. Trudeau).

Mutations were predicted as stabilizing if they exhibited ΔΔ*G*~calc~\<−0.45 R.e.u. and destabilizing otherwise.

###### 

Stability and Kinetic Parameters of Human and Designed AChE Variants

  AChE Variant        Mut[a](#tblfn3){ref-type="table-fn"}   Normalized Activity[b](#tblfn4){ref-type="table-fn"}   Inactivation Temperature (°C)[c](#tblfn5){ref-type="table-fn"}   *k*~*i*~ (*S*~P~-VX) × 10^7^ (M^−1^min^−1^)   ACh Hydrolysis                                                                                                    
  ------------------- -------------------------------------- ------------------------------------------------------ ---------------------------------------------------------------- --------------------------------------------- ------------------------------------- ------------------------------------- ------------------------------------- -------------------------------------
  hAChE (HEK293)      --                                     --                                                     --                                                               50.6 ± 0.3                                    7.92 ± 0.15                           0.09 ± 0.01                           3.8 ± 0.2                             4.4 ± 0.6
  hAChE (bacterial)   --                                     1                                                      44 ± 0.4                                                         ND[d](#tblfn6){ref-type="table-fn"}           ND[d](#tblfn6){ref-type="table-fn"}   ND[d](#tblfn6){ref-type="table-fn"}   ND[d](#tblfn6){ref-type="table-fn"}   ND[d](#tblfn6){ref-type="table-fn"}
  dAChE1              17                                     119 ± 20                                               60.5 ± 0.4                                                       ND[d](#tblfn6){ref-type="table-fn"}           6.48 ± 0.71                           0.050 ± 0.006                         4.4 ± 0.1                             8.7 ± 1.1
  dAChE2              30                                     280 ± 40                                               61.5 ± 0.5                                                       67.1 ± 0.3                                    ND[d](#tblfn6){ref-type="table-fn"}   ND[d](#tblfn6){ref-type="table-fn"}   ND[d](#tblfn6){ref-type="table-fn"}   ND[d](#tblfn6){ref-type="table-fn"}
  dAChE3              42                                     308 ± 44                                               62.3 ± 0.2                                                       69.4 ± 0.3                                    2.65 ± 0.52                           0.177 ± 0.010                         4.4 ± 0.1                             2.5 ± 0.2
  dAChE4              51                                     1770 ± 258                                             62.3 ± 0.3                                                       66.2 ± 1.2                                    7.60 ± 0.34                           0.071 ± 0.007                         2.73 ± 0.07                           3.9 ± 0.4
  dAChE5              67                                     637 ± 134                                              61.1 ± 0.2                                                       68.5 ± 0.6                                    6.47 ± 0.82                           0.104 ± 0.010                         3.16 ± 0.01                           3.0 ± 0.3

Number of amino acid mutations relative to wild-type hAChE.

Activity in crude lysates of cells expressing the AChE variants from 250 ml *E. coli* cultures.

The temperature at which 50% of activity was retained. Enzyme samples were incubated for 30 min at varying temperatures and tested for AChE activity after cooling.

Not determined.

###### 

Stability and Kinetic Parameters of PTE Variants

  Variant   Mut[a](#tblfn7){ref-type="table-fn"}   Normalized Activity[b](#tblfn8){ref-type="table-fn"}   Inactivation Temperature (°C)   *T*~*1/2*~ Chelator[c](#tblfn9){ref-type="table-fn"} (min)   K~M~ (mM)[d](#tblfn10){ref-type="table-fn"}   *k*~cat~ × 10^5^ (min^-1^) [d](#tblfn10){ref-type="table-fn"}   *k*~cat~/K~M~ × 10^9^ (min^-1^M^-1^) [d](#tblfn10){ref-type="table-fn"}   
  --------- -------------------------------------- ------------------------------------------------------ ------------------------------- ------------------------------------------------------------ --------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------- --------------------------------------
  PTE-S5    3                                      1                                                      50.9 ± 0.7                      52.4 ± 0.2                                                   7.5 ± 0.3                                     0.101 ± 0.023                                                   0.970 ± 0.076                                                             0.96 ± 0.33
  dPTE1     9                                      2.0                                                    54.7 ± 3.2                      ND[e](#tblfn11){ref-type="table-fn"}                         ND[e](#tblfn11){ref-type="table-fn"}          ND[e](#tblfn11){ref-type="table-fn"}                            ND[e](#tblfn11){ref-type="table-fn"}                                      ND[e](#tblfn11){ref-type="table-fn"}
  dPTE2     19                                     6.1                                                    59.2 ± 0.7                      62.0 ± 0.2                                                   51.2 ± 5.1                                    0.060 ± 0.014                                                   0.70 ± 0.05                                                               1.17 ± 0.35
  dPTE3     28                                     2.3                                                    47.0 ± 1.3                      ND[e](#tblfn11){ref-type="table-fn"}                         ND[e](#tblfn11){ref-type="table-fn"}          ND[e](#tblfn11){ref-type="table-fn"}                            ND[e](#tblfn11){ref-type="table-fn"}                                      ND[e](#tblfn11){ref-type="table-fn"}

Number of mutations relative to wild-type PTE.

Fold increase in activity in crude *E. coli* lysates relative to PTE-S5.

Chelator, 50 μM 1,10-phenanthroline.

Kinetic parameters for paraoxon.

ND, not determined.

###### 

Structure and Sequence Features of Designed Variants Compared to Their Wild-Type Counterparts

  Design Variant   aa[a](#tblfn12){ref-type="table-fn"}   Mut[b](#tblfn13){ref-type="table-fn"}   Core[c](#tblfn14){ref-type="table-fn"}   Salt Bridges[d](#tblfn15){ref-type="table-fn"}   H Bonds[d](#tblfn15){ref-type="table-fn"}   X → Pro[e](#tblfn16){ref-type="table-fn"}   Charge N/P[d](#tblfn15){ref-type="table-fn"}^,^[f](#tblfn17){ref-type="table-fn"}   pI[g](#tblfn18){ref-type="table-fn"}   
  ---------------- -------------------------------------- --------------------------------------- ---------------------------------------- ------------------------------------------------ ------------------------------------------- ------------------------------------------- ----------------------------------------------------------------------------------- -------------------------------------- -----
  dAChE1           530                                    17 (3%)                                 9 (53%)                                  3                                                14                                          1                                           1/2                                                                                 5.5                                    5.5
  dAChE2           30 (6%)                                15 (50%)                                4                                        11                                               3                                           4/4                                         5.5                                                                                                                        
  dAChE3           42 (8%)                                16 (38%)                                5                                        18                                               6/6                                         5.5                                                                                                                                                                    
  dAChE4           51 (10%)                               17 (33%)                                3                                        10                                               7/8                                         5.5                                                                                                                                                                    
  dAChE5           67 (13%)                               19 (28%)                                10                                       15                                               5                                           7/9                                         5.6                                                                                                                        
  dPTE1            331                                    9 (3%)                                  0 (0%)                                   3                                                5                                           0                                           6/−2                                                                                5.3                                    6.7
  dPTE2            19 (6%)                                2 (11%)                                 8                                        9                                                11/−2                                       5.0                                                                                                                                                                    
  dPTE3            28 (9%)                                5 (18%)                                 12                                       7                                                16/−3                                       4.8                                                                                                                                                                    
  dSIRT6           280                                    11 (4%)                                 1 (9%)                                   0                                                4                                           1                                           0/0                                                                                 8.3                                    8.3
  dDnmt3           272                                    14 (5%)                                 0 (0%)                                   4                                                7                                           1                                           1/1                                                                                 8.4                                    8.6
  dMyoc-OLF        259                                    21 (8%)                                 2 (10%)                                  2                                                4                                           0                                           −2/1                                                                                5.4                                    5.0

Number of amino acids in the PDB structure (per monomer); the design algorithm ignores all protein segments that are absent from the structure.

Number of amino acid mutations in the design compared to wild-type; in brackets, as percentage of total number of amino acids.

Number of mutations in protein core. In brackets, as percentage of total number of mutations.

Difference compared to wild-type structure. Positive values indicate higher number in design than wild-type.

Number of mutations to proline.

Mutations to negative (D/E) and positive (K/R) amino acids are indicated to the left and right of the slash, respectively.

Isoelectric point: des refers to designed variant, and WT refers to wild-type.
